39 completed, 5 terminated, 3 active not recruiting, 2 recruiting. 27 Phase 2, 12 Phase 1, 10 Not applicable, 2 Phase 3.
Follow Chronic Phase Chronic Myelogenous Leukemia: new trials by email Literature Review of Chronic Phase Chronic Myelogenous Leukemia trials Research Report on Chronic Phase Chronic Myelogenous Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia Interview - Chronic Myeloid Leukemia, Chronic Phase Chronic Myelogenous Leukemia | Recruiting | University of California, Irvine | 75 | 2024-01-25 | 2026-03-10 | |
| Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation Asciminib 40 MG, Asciminib 40 MG Twice Daily, Asciminib 80 MG daily - Chronic Phase Chronic Myelogenous Leukemia | Phase 2 | Recruiting | Medical College of Wisconsin | 51 | 2021-11-11 | 2026-08-25 |
| ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase Dasatinib, Decitabine and Cedazuridine - Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 39 | 2021-10-21 | 2026-10-02 |
| A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors Online Mindfulness Meditation, Internet-Based Webinars - Myeloproliferative Neoplasm, Chronic Phase Chronic Myelogenous Leukemia | Not applicable | Completed | University of California, San Francisco | 47 | 2020-09-18 | 2023-02-13 |
| Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Bosutinib - Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia | Phase 1 / Phase 2 | Active not recruiting | Children's Oncology Group | 60 | 2020-07-06 | 2026-10-01 |
| A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia Text Message-Based Navigation Intervention, Survey Administration - Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia | Not applicable | Completed | Thomas Jefferson University | 30 | 2020-06-05 | 2025-04-29 |
| Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor Chronic Phase Chronic Myelogenous Leukemia | Unknown | Assiut University | 45 | 2019-10-01 | 2019-09-30 | |
| CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey Chronic Phase Chronic Myelogenous Leukemia, Accelerated Phase Chronic Myelogenous Leukemia | Completed | Incyte Biosciences UK | 427 | 2017-12-18 | 2021-08-16 | |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies therapeutic allogeneic lymphocytes, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | University of Chicago | 77 | 2013-04-04 | 2019-08-07 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant management of therapy complications, musculoskeletal complications management/prevention - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Withdrawn | Roswell Park Cancer Institute | 2012-05-01 | 2012-07-09 | |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies fludarabine phosphate, melphalan, total-body irradiation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Roswell Park Cancer Institute | 94 | 2012-02-28 | 2019-09-24 |
| Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate dasatinib, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 | Terminated | National Cancer Institute (NCI) | 4 | 2011-09-01 | 2014-04-02 |
| Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 43 | 2011-09-01 | 2017-05-19 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant infection prophylaxis and management, laboratory biomarker analysis, flow cytometry - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Active not recruiting | City of Hope Medical Center | 153 | 2011-01-11 | 2026-10-22 | |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2011-01-01 | 2014-04-29 |
| Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer palifermin, flow cytometry, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Completed | Martin, Paul | 6 | 2010-09-01 | 2014-04-02 |
| Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies umbilical cord blood transplantation, fludarabine phosphate, cyclophosphamide - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | Nohla Therapeutics, Inc. | 15 | 2010-08-01 | 2019-03-05 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload deferasirox - Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2010-07-01 | 2019-06-18 |
Showing 20 of 51. Sign in to see all of them.
Leukemia, Myeloid, Chronic-Phase (51) · Leukemia, Myeloid, Accelerated Phase (36) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (33) · Leukemia, Lymphocytic, Chronic, B-Cell (30) · Leukemia, Myeloid, Acute (29) · Burkitt Lymphoma (28) · Lymphoma, B-Cell, Marginal Zone (28) · Lymphoma, Follicular (28) · Congenital Abnormalities (27) · Lymphoma, Large B-Cell, Diffuse (27) · Lymphoma, Mantle-Cell (27) · Blast Crisis (25) · Hodgkin Disease (25) · Lymphoma, Non-Hodgkin (25) · Lymphoma, T-Cell, Cutaneous (25)
Bone Marrow Diseases (51) · Chronic Disease (51) · Disease Attributes (51) · Hematologic Diseases (51) · Hemic and Lymphatic Diseases (51) · Leukemia, Myeloid (51) · Neoplasms (51) · Neoplasms by Histologic Type (51) · Pathologic Processes (51) · Pathological Conditions, Signs and Symptoms (51) · Leukemia (49) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (34) · Immune System Diseases (33) · Immunoproliferative Disorders (33) · Leukemia, Lymphoid (33)
Cyclosporine (13) · fludarabine phosphate (13) · Mycophenolic Acid (11) · Whole-Body Irradiation (11) · Peripheral Blood Stem Cell Transplantation (10) · Cyclophosphamide (6) · Imatinib Mesylate (6) · Methotrexate (5) · Tacrolimus (5) · merphos (5) · Busulfan (4) · Therapeutics (4) · Transplantation (4) · Antilymphocyte Serum (3) · Cyclosporins (3)
Fred Hutchinson Cancer Center (15) · National Cancer Institute (NCI) (13) · Children's Oncology Group (3) · City of Hope Medical Center (3) · Roswell Park Cancer Institute (3) · Case Comprehensive Cancer Center (2) · Assiut University (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · Incyte Biosciences UK (1) · M.D. Anderson Cancer Center (1) · Martin, Paul (1) · Medical College of Wisconsin (1) · Nohla Therapeutics, Inc. (1) · Thomas Jefferson University (1) · University of California, Irvine (1)
United States (48) · Italy (5) · Germany (3) · United Kingdom (2) · Canada (1) · France (1) · Ireland (1) · Netherlands (1) · Spain (1) · Switzerland (1)
Brenda Sandmaier (4) · Paul Martin (3) · Colleen Delaney (2) · George Chen (2) · Ryotaro Nakamura (2) · Ann Woolfrey (1) · B. Smith (1) · Brenda Cooper, MD (1) · Christopher Porter (1) · David Maloney (1) · Ehab Atallah, MD (1) · Elias Jabbour (1) · Gregory Yanik, MD (1) · H. Joachim Deeg (1) · Hillard Lazarus (1)
PMID 32499241, PMID 18698002, PMID 19900571, PMID 21465636, PMID 22259028, PMID 24474568, PMID 26764356, PMID 26853648, PMID 28817727, PMID 30562587, PMID 32628342, PMID 33420905, PMID 35445027, PMID 36282798, PMID 38033284
P30CA015704 (11), P01CA018029 (6), U10CA098543 (3), RC2HL101844 (2), U10CA031946 (2), 2015 (1), 2023 (1), N01CM17003 (1), N01CM62202 (1), P01CA015396 (1), P01CA078902 (1), P01HL036444 (1), P30CA046592 (1), P30CA046934 (1), R01CA112631 (1)